Floatz logo

dk210

Kidney Cancer

DEKA BiosciencesPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Kidney Cancer cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Dartmouth-Hitchcock Medical Center
Phase 3BBB
Girentuximab
Memorial Sloan Kettering Cancer Center
Phase 3BB
Girentuximab
Heidelberg Pharma AG
Phase 3BB
ETOPOSIDE
City of Hope Medical Center
Phase 3BB
FLUOROURACILUM
Medical Research Council
Phase 3BB

View all 50 →

Same molecule, other indications

dk210 is also rated in:

female reproductive organ cancerDormant
CC
Indicative ·
41 / 100
View asset →
skin cancerDormant
CC
Indicative ·
41 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →